Dezofemin 30 – a hormonal contraceptive for system use.

Structure

• active ingredients: ethinylestradiol, dezogestret;
• 1 tablet, film coated, contains ethinylestradiol 0.03 mg, dezogestret 0.15 mg;
• other components: lactoses monohydrate, starch corn, maltodextrin, the transparent isolating mix for a covering, sodium salt of glikolyaty starch (type A), alpha tocopherol, white mix for a film covering.

Contraindication

Combined Hormonal Contraceptives (CHC) cannot be applied in the presence of any following states. In case any of these states or diseases arises for the first time at use of KGK, administration of medicament should be stopped immediately.

Hypersensitivity to active ingredients or to medicament components.

Presence of risk factors of developing of a venous thrombembolia (VTE):

• a venous thrombembolia – existence of VTE now (at use of anticoagulants) or in the anamnesis (for example, the deep vein thrombosis (DVT) or a pulmonary embolism (TELA);
hereditary or acquired tendency to a venous thrombembolia, such as resistance to the activated protein With (including the V Lyayden's factor), deficiency of antithrombin III, deficit of a protein of C, deficit of a protein of S is known to
• ;
• big surgical interventions with a long immobilization;
risk of developing of a venous thrombembolia because of presence of many risk factors is high
• .

Presence of risk factors of developing of an arterial thrombembolia (ATE):

• an arterial thrombembolia – presence of an arterial thrombembolia now, presence of an arterial thrombembolia in the anamnesis (for example, a myocardial infarction) or a prodromal state (for example, stenocardia);
• a cerebrovascular disease – a stroke now, a stroke in the anamnesis or a prodromal state (for example, the ischemic tranzitorny attack (TIA);
hereditary or acquired tendency to an arterial thrombembolia, such as gipergomotsisteinemiya and existence of antibodies to phospholipids is known to
• (antibodies to cardiolipins, lupoid anticoagulant);
• existence in the anamnesis of migraine with focal neurologic symptomatology;
• high risk of developing of an arterial thrombembolia because of presence of many risk factors.

Pancreatitis, including in the anamnesis if it is connected with a heavy gipertriglitseridemiya.

Existence now or in the anamnesis of a serious illness of a liver (so far indicators of function of a liver will not return to norm).

Existence now or in the anamnesis of tumors of a liver (benign or malignant).

Side reactions

At use CHC (the combined hormonal contraceptives) observed the increased risk of developing an arterial and venous thrombembolia, including a myocardial infarction, paralysis, ischemic tranzitorny disturbance of cerebral circulation, a deep vein thrombosis and an embolism of pulmonary vessels.

At use of all KGK observed changes in the nature of vaginal bleeding, especially in the first months of use, changes of frequency of bleeding (absence, smaller frequency, big frequency or a long time), intensity of bleeding (reduction or increase) or the general duration of vaginal bleeding were also fixed.

Route of administration

For oral administration.

Dosage

Within 21 days is accepted on 1 tablet. A pill from the following packing begins to be taken after the 7-day period without reception of tablets during which usually there is cancellation bleeding. As a rule, it begins for 2.3 day after application of the last tablet and can proceed prior to application of tablets from the following packing.

How to accept Dezofemin 30

Pill should be taken in the order specified on packing, daily, approximately at the same time, washing down if necessary with a small amount of liquid.

Feature of application

Use during pregnancy or feeding by a breast

Pregnancy is a contraindication to application Dezofemin 30. If the woman became pregnant during application Dezofemin 30, further application should be stopped. Results of epidemiological researches do not indicate increase in risk of congenital defects at children whose mothers accepted KGK before pregnancy, as well as a possibility of teratogenic action at inadvertent reception of KGK in the early stages of pregnancy.

KGK can influence a lactation as they can reduce quantity and change structure of breast milk. Thus, application of KGK usually is not recommended before the full end of the period of feeding by a breast. With milk small amounts of contraceptive steroids and/or their metabolites can be distinguished, but there are no proofs that it has negative effect on health of babies.

Children

Are not present clinical data on efficiency and safety of use of medicine to children (up to 18 years).

Ability to influence speed of response at control of motor transport or other mechanisms

Drug does not affect speed of reaction at control of motor transport or other mechanisms.

Overdose

About serious and dangerous complications at overdose it was not reported. At overdose there can be following symptoms: nausea, vomiting, girls have insignificant bloody discharges from a vagina. Antidotes do not exist, and treatment of overdose has to be symptomatic.

to Store

in original packing at a temperature not above 30ºС. To store out of children's reach.